Prednisone (Prednisone) Patent Expiration, LOE Window & CMS Spending
Prednisone (Prednisone) by Boehringer Ingelheim: Off-Patent Genericized (AB Competition), 21 AB generics, $120.2M 2024 CMS Part D & Medicaid spend, and $2,348 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Boehringer Ingelheim |
| FDA Application & Pathway | N017109 (NDA) |
| Exclusivity / Cliff Horizon | Off-Patent Genericized (AB Competition) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 21 |
| 2024 CMS Total Public Spend | $120.2M |
| 2024 Medicare Part D Spend | $65.2M |
| 2024 Medicaid Spend | $55.0M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($2,348 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.